Drug Profile
INX 005
Alternative Names: INX-005Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cardiff University; Katholieke Universiteit Leuven; University of Georgia
- Developer Inhibitex
- Class Antivirals; Purine nucleosides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
- 30 Nov 2011 Preclinical trials in Hepatitis C in USA (PO)